<DOC>
	<DOCNO>NCT02687191</DOCNO>
	<brief_summary>This study employ modify continual reassessment method ( mCRM ) design estimate maximum tolerate dose ( MTD ) PF-05230907 , define target toxicity rate 15 % base treatment emergent thromboembolic and/or ischemic event ( TIEs ) . The mCRM design utilizes Bayesian methodology continuously learn dose-toxicity relationship , characterize parametric model . Subjects diagnosis ICH ( determine compute tomography ) enrol cohort 3 . The total length time plan study participation approximately 3 month ; 6.0 hour screen , single dose administration 4-day minimum hospital confinement period follow-up visit Day 91 . Severity adverse event ( AEs ) serious adverse event ( SAEs ) grade accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.03 . All subject receive PF-05230907 evaluable TIEs . The determination MTD use mCRM model base TIEs occur 7 day post-dose ( Day 8 ) .</brief_summary>
	<brief_title>Safety Tolerability PF-05230907 Intracerebral Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<criteria>ICH document CT scan within 6.0 hour symptom onset Baseline ICH volume &gt; 5mL &lt; 60 mL Deep coma ( Glasgow Coma Scale &lt; 6 ) Modified Rankin Score &gt; 3 prior ICH onset Known history schemic , vasoocclusive thrombotic event within 6 month prior screen Known prothrombotic disorder Known secondary ICH relate aneurysm , arteriovenous malformation , subarachnoid hemorrhage , trauma , cause . CT angiography , MR , diagnostic study obtain part standard care may use ass eligibility . Known use oral anticoagulant ( ) Known use lowmolecular weight heparin heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>safety , maximum tolerate dose , modified continual reassessment method , intracerebral , hemorrhage , hematoma</keyword>
</DOC>